Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 04, 2025 01:00 ET | Source: Addex Therapeutics

Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 4, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a...
December 01, 2025 01:00 ET | Source: Addex Therapeutics

Addex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025

Geneva, Switzerland, December 1, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric...
October 29, 2025 02:00 ET | Source: Addex Therapeutics

Addex Increases Issued Share Capital to Create Treasury Shares

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 29, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a...
September 30, 2025 01:00 ET | Source: Addex Therapeutics

Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update

Cash position of CHF 2.3 million at end of H1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to phase 2 mGlu2 PAM asset,...
September 26, 2025 01:00 ET | Source: Addex Therapeutics

Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025

Geneva, Switzerland, September 26, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric...
September 23, 2025 01:00 ET | Source: Addex Therapeutics

Addex Appoints Bank of New York Mellon as Depositary Bank

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 23, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a...
June 30, 2025 01:00 ET | Source: Addex Therapeutics

Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland – June 30, 2025 – Addex Therapeutics (SIX: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel...
June 25, 2025 01:00 ET | Source: Addex Therapeutics

Addex Shareholders Approve All Resolutions at Annual General Meeting

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
June 19, 2025 01:00 ET | Source: Addex Therapeutics

Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update

Strong cash position of CHF2.8 million at end of Q1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to our phase 2 mGlu2 PAM asset,...
June 18, 2025 01:00 ET | Source: Addex Therapeutics

Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025

Geneva, Switzerland, June 18, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators...